U.S. markets open in 8 hours 28 minutes
  • S&P Futures

    3,856.75
    +11.75 (+0.31%)
     
  • Dow Futures

    31,154.00
    +58.00 (+0.19%)
     
  • Nasdaq Futures

    13,375.25
    +81.00 (+0.61%)
     
  • Russell 2000 Futures

    2,159.90
    +2.20 (+0.10%)
     
  • Crude Oil

    53.28
    +0.04 (+0.08%)
     
  • Gold

    1,873.50
    +7.00 (+0.38%)
     
  • Silver

    26.07
    +0.30 (+1.16%)
     
  • EUR/USD

    1.2137
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.0900
    0.0000 (0.00%)
     
  • Vix

    21.58
    -1.66 (-7.14%)
     
  • GBP/USD

    1.3695
    +0.0060 (+0.44%)
     
  • USD/JPY

    103.3730
    -0.5190 (-0.50%)
     
  • BTC-USD

    34,616.61
    -46.01 (-0.13%)
     
  • CMC Crypto 200

    684.89
    -15.73 (-2.24%)
     
  • FTSE 100

    6,740.39
    +27.44 (+0.41%)
     
  • Nikkei 225

    28,714.22
    +80.76 (+0.28%)
     

Biotech News: Why Advaxis Stock Is Soaring Today

William White
Biotech News: Why Advaxis Stock Is Soaring Today

Advaxis stock is flying high Monday on news concerning a Phase1/2 study of ADXS-PSA.Source: Shutterstock ADXS-PSA is Advaxis' (NASDAQ:ADXS) Listeria monocytogenes-based immunotherapies. The drug is being evaluated for use on its own, as well as with Merck's (NYSE:MRK) anti-PD-1 therapy.The study of ADXS-PSA is broken up into two separate parts. The first is Part A, which focuses on the drug's effectiveness when used on its own. The second is Part B, which tests how it does alongside MRK's drug.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe important biotech news from Advaxis today has to do with the Part B portion of the study. New from this study shows that it is performing well when it comes to tolerability. There have been no major adverse events or additive toxicity.Another strong point from the Part B section of the study includes response from T-cell's to ADXS-PSA. There was a reaction from T-cells in 75% of subjects. It's also worth noting that antigen spreading was seen in 85% of subjects.More data from the ADXS-PSA study also finds patients taking part in the study to have a long survival rate. At the cutoff time for the data in this report, the median survival rate for patients in te study was 21.1 months. * The Elite 8 Stocks to Buy for Massive Outperformance Based on the prolonged survival data and strong safety profile to date, we believe that continued clinical development of ADXS-PSA in combination with KEYTRUDA® is warranted and represents a potentially significant opportunity for Advaxis," Kenneth Berlin, President and CEO of Advaxis, said in a statement.ADXS stock was up 16% as of noon Monday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Tech Stocks That Transformed Their Business * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos * 7 Weak Blue-Chip Stocks to Trim Immediately As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Biotech News: Why Advaxis Stock Is Soaring Today appeared first on InvestorPlace.